Article

Isis appoints Dr. Jonas as executive vice president

Carlsbad, CA-Jeffrey M. Jonas, MD, joined Isis Pharmaceuticals Inc. Feb. 1 as executive vice president. He will lead clinical development, preclinical development, regulatory affairs, quality assurance, and compliance at the company.

Carlsbad, CA-Jeffrey M. Jonas, MD, joined Isis Pharmaceuticals Inc. Feb. 1 as executive vice president. He will lead clinical development, preclinical development, regulatory affairs, quality assurance, and compliance at the company.

Dr. Jonas will be broadly responsible for the entire pipeline, both partnered and unpartnered, and contribute to portfolio management. In addition, he will be a principal representative of the company, interacting with investors and partners, working with Kate Corcoran, PhD, vice president, corporate development.

Prior to joining Isis, Dr. Jonas was chief medical officer and executive vice president at Forest Laboratories Inc., where he was responsible for clinical development, medical affairs, pharmacovigilence, and external scientific affairs.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
© 2025 MJH Life Sciences

All rights reserved.